{"pmid":32407706,"pmcid":"PMC7219427","title":"SARS-CoV-2: A New Song Recalls an Old Melody.","text":["SARS-CoV-2: A New Song Recalls an Old Melody.","The viruses causing the SARS outbreak of 2002-2003 and current COVID-19 pandemic are related betacoronaviruses. What insights were learned from SARS that can inform SARS-CoV-2 vaccine development? Focusing on important lessons from SARS vaccine development and two SARS vaccines evaluated in humans may guide SARS-CoV-2 vaccine design, testing, and implementation.","Cell Host Microbe","Subbarao, Kanta","32407706"],"abstract":["The viruses causing the SARS outbreak of 2002-2003 and current COVID-19 pandemic are related betacoronaviruses. What insights were learned from SARS that can inform SARS-CoV-2 vaccine development? Focusing on important lessons from SARS vaccine development and two SARS vaccines evaluated in humans may guide SARS-CoV-2 vaccine design, testing, and implementation."],"journal":"Cell Host Microbe","authors":["Subbarao, Kanta"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407706","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.chom.2020.04.019","topics":["Treatment"],"weight":1,"_version_":1666950579760398338,"score":9.490897,"similar":[{"pmid":32328406,"pmcid":"PMC7177048","title":"Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","text":["Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.","The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19.","Infect Dis Ther","Padron-Regalado, Eriko","32328406"],"abstract":["The emergence of the strain of coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and its impact on global health have made imperative the development of effective and safe vaccines for this lethal strain. SARS-CoV-2 now adds to the list of coronavirus diseases that have threatened global health, along with the SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) coronaviruses that emerged in 2002/2003 and 2012, respectively. As of April 2020, no vaccine is commercially available for these coronavirus strains. Nevertheless, the knowledge obtained from the vaccine development efforts for MERS and SARS can be of high value for COVID-19 (coronavirus disease 2019). Here, we review the past and ongoing vaccine development efforts for clinically relevant coronavirus strains with the intention that this information helps in the development of effective and safe vaccines for COVID-19. In addition, information from naturally exposed individuals and animal models to coronavirus strains is described for the same purpose of helping into the development of effective vaccines against COVID-19."],"journal":"Infect Dis Ther","authors":["Padron-Regalado, Eriko"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32328406","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s40121-020-00300-x","keywords":["covid-19","coronavirus","mers","sars","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1666138494558273536,"score":137.85976},{"pmid":32378471,"title":"Animal Models for Emerging Coronavirus: Progress and New Insights.","text":["Animal Models for Emerging Coronavirus: Progress and New Insights.","The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases.","Emerg Microbes Infect","Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao","32378471"],"abstract":["The emergences of coronaviruses have caused a serious global public health problem because their infection in humans caused the severe acute respiratory disease and deaths. The outbreaks of lethal coronaviruses have taken place for three times within recent two decades (SARS-CoV in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019). Much more serious than SARS-CoV in 2002, the current SARS-CoV-2 infection has been spreading to more than 213 countries, areas or territories and causing more than two million cases up to date (April 17, 2020). Unfortunately, no vaccine and specific anti-coronavirus drugs are available at present time. Current clinical treatment at hand is inadequate to suppress viral replication and inflammation, and reverse organ failure. Intensive research efforts have focused on increasing our understanding of viral biology of SARS-CoV-2, improving antiviral therapy and vaccination strategies. The animal models are important for both the fundamental research and drug discovery of coronavirus. This review aims to summarize the animal models currently available for SARS-CoV and MERS-CoV, and their potential use for the study of SARS-CoV-2. We will discuss the benefits and caveats of these animal models and present critical findings that might guide the fundamental studies and urgent treatment of SARS-CoV-2-caused diseases."],"journal":"Emerg Microbes Infect","authors":["Yuan, Lunzhi","Tang, Qiyi","Cheng, Tong","Xia, Ningshao"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378471","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/22221751.2020.1764871","keywords":["animal model","coronavirus","infectious disease","respiratory syndrome","vaccine and drug discovery"],"topics":["Treatment"],"weight":1,"_version_":1666597097458106368,"score":137.4902},{"pmid":32259480,"pmcid":"PMC7136867","title":"SARS-CoV-2 Vaccines: Status Report.","text":["SARS-CoV-2 Vaccines: Status Report.","SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.","Immunity","Amanat, Fatima","Krammer, Florian","32259480"],"abstract":["SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population."],"journal":"Immunity","authors":["Amanat, Fatima","Krammer, Florian"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259480","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.immuni.2020.03.007","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493105995779,"score":134.35599},{"pmid":32219057,"pmcid":"PMC7094941","title":"The SARS-CoV-2 Vaccine Pipeline: an Overview.","text":["The SARS-CoV-2 Vaccine Pipeline: an Overview.","Purpose of Review: The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Recent Findings: Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time.","Curr Trop Med Rep","Chen, Wen-Hsiang","Strych, Ulrich","Hotez, Peter J","Bottazzi, Maria Elena","32219057"],"abstract":["Purpose of Review: The goal of this review is to provide a timely overview on efforts to develop a vaccine for the 2019 novel coronavirus SARS-CoV-2, the causative agent of coronavirus disease (COVID-19). Recent Findings: Previous research efforts to develop a severe acute respiratory syndrome coronavirus (SARS-CoV) vaccine in the years following the 2003 pandemic have opened the door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will require careful safety evaluations for immunopotentiation that could lead to increased infectivity or eosinophilic infiltration. Besides this, a COVID-19 vaccine target product profile must address vaccinating at-risk human populations including frontline healthcare workers, individuals over the age of 60, and those with underlying and debilitating chronic conditions. Among the vaccine technologies under evaluation are whole virus vaccines, recombinant protein subunit vaccines, and nucleic acid vaccines. Summary: Each current vaccine strategy has distinct advantages and disadvantages. Therefore, it is paramount that multiple strategies be advanced quickly and then evaluated for safety and efficacy. Ultimately, the safety studies to minimize undesired immunopotentiation will become the most significant bottleneck in terms of time."],"journal":"Curr Trop Med Rep","authors":["Chen, Wen-Hsiang","Strych, Ulrich","Hotez, Peter J","Bottazzi, Maria Elena"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219057","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1007/s40475-020-00201-6","keywords":["covid-19","coronavirus","rbd","receptor binding domain","wuhan virus"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492278669313,"score":131.31104},{"pmid":32437926,"title":"From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.","text":["From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.","The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics.","Microbes Infect","Ma, Cuiqing","Su, Shan","Wang, Jiachao","Wei, Lin","Du, Lanying","Jiang, Shibo","32437926"],"abstract":["The global pandemic of COVID-19 caused by SARS-CoV-2 (also known as 2019-nCoV and HCoV-19) has posed serious threats to public health and economic stability worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines for the development of SARS-CoV-2 vaccines. In this review, we summarized the current knowledge on the advantages and disadvantages of the SARS-CoV vaccine candidates and prospected the strategies for the development of safe, effective and broad-spectrum coronavirus vaccines for prevention of infection by currently circulating SARS-CoV-2 and other emerging and reemerging coronaviruses that may cause future epidemics or pandemics."],"journal":"Microbes Infect","authors":["Ma, Cuiqing","Su, Shan","Wang, Jiachao","Wei, Lin","Du, Lanying","Jiang, Shibo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437926","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.micinf.2020.05.004","keywords":["2019-ncov","cross-protection","hcov-19","human coronavirus","sars-cov","sars-cov-2","vaccine"],"topics":["Treatment"],"weight":1,"_version_":1667521393508483072,"score":130.35457}]}